Eolas Therapeutics, Inc.
Records under this name other than patents Eolas Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 7 of 7 · Back to Eolas Therapeutics, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,440,982 | Substituted prolines/piperidines as orexin receptor antagonists Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,499,517 | Substituted prolines / piperidines as orexin receptor antagonists Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,221,170 | Difluoropyrrolidines as Orexin Receptor Modulators Formerly held In force · High confidence | In force | High confidence | |
| US 10,894,789 | Halo-Substituted Piperidines as Orexin Receptor Modulators Formerly held In force · High confidence | In force | High confidence | |
| US 11,434,236 | Halo-Substituted Piperidines as Orexin Receptor Modulators Formerly held In force · High confidence | In force | High confidence | |
| US 12,084,437 | Halo-Substituted Piperidines as Orexin Receptor Modulators Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 9,896,452 | Substituted prolines/piperidines as orexin receptor antagonists Formerly held Lapsed on the fee record Ended Feb 20, 2026 · From the USPTO record | Lapsed on the fee record | Ended Feb 20, 2026 | From the USPTO record |